Actionable news
0
All posts from Actionable news
Actionable news in NUVA: NuVasive, Inc.,

Nuvasive Reports Third Quarter 2015 Financial Results

The following excerpt is from the company's SEC filing.

Third Quarter 2015 Highlights:

Revenue increased 5.6% to $200.5 million, or 7.8% on a constant currency basis;

Non-GAAP operating profit margin increased 460 basis points to 16.3%; GAAP operating profit margin of 14.0%;

Adjusted EBITDA margin increased 540 basis points to 26.7%;

Non-GAAP net income of $18.1 million; GAAP net income of $13.0 million;

Non-GAAP diluted earnings per share of $0.35; GAAP diluted earnings per share of $0.24; and

Company reiterates 2015 revenue outlook and increases non-GAAP operating profit margin, adjusted EBITDA and EPS guidance

NuVasive, Inc. (Nasdaq: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, announced today financial results for the quarter ended September 30, 2015.

We are pleased to report another strong quarter in which we achieved revenue growth of nearly 8% on a constant currency basis in line with our mid to high single-digit growth goal and profitability that once again significantly outperformed our expectations, said Gregory T. Lucier, Chairman and Chief Executive Officer of NuVasive. By remaining focused on our margin expansion initiatives across the Company, we delivered incredibly strong year-over-year growth in non-GAAP operating profit margin and adjusted EBITDA margin, improving 460 and 540 basis points, respectively, while non-GAAP EPS increased nearly three and a half times compared to the same quarter last year.

Our performance for the quarter was driven by continued strength in the United States and robust growth in certain international geographies where NuVasive is leading with our competitive XLIF

technology and differentiated offerings. We remain confident that our unrelenting focus on innovation and technology, increased operational efficiencies, international scalability and our commitment to increased self-manufacturing position NuVasive to be the leader in transforming spine and improving patient outcomes, said Mr. Lucier.

A full reconciliation of non-GAAP to GAAP measures can be found in the tables of this news release.

Third Quarter 2015 Results

NuVasive reported third quarter 2015 total revenue of $200.5 million, a 5.6% increase compared to $189.9 million for the third quarter 2014. On a constant currency basis, third quarter 2015 total revenue increased 7.8% compared to the same period last year.

GAAP gross profit for the third quarter 2015 was $151.4 million and gross margin was 75.5% compared to a gross profit of $142.2 million and a gross margin of 74.9% for the third quarter 2014. Total GAAP operating expenses for the third quarter 2015 were $123.3 million compared to $125.9 million in the third quarter 2014.

The Company reported a GAAP net income of $13.0 million, or $0.24 per share, for the third quarter 2015 compared to a GAAP net loss of $(1.8) million, or $(0.04) per share, for the third quarter 2014.

On a non-GAAP basis, the Company reported net income of $18.1 million, or $0.35 per share, for the third quarter 2015 compared to net income of $3.9 million, or $0.08 per share, for the third quarter 2014.

Cash, cash equivalents and short and long-term marketable securities were approximately $451.2 million at September 30, 2015.

Annual Guidance for 2015

The Company provided the following updated projections to its full year 2015 guidance:

Revenue of approximately $810.0 million, which includes an approximate $13.0 million of currency headwinds, or approximately 6.2% growth compared to revenue of $762.4 million for 2014; on a constant currency basis revenue is expected to grow approximately 7.9%;

GAAP diluted earnings per share of approximately $1.24 compared to GAAP loss per diluted share of $(0.36) for 2014; versus a prior expectation of $1.18 for 2015;

Non-GAAP diluted earnings per share of approximately $1.25, an increase of approximately 86.6% compared to non-GAAP diluted earnings of $0.67 for 2014; versus a prior expectation of $1.17 for 2015;

Non-GAAP operating profit margin of approximately 15.2%, an increase of approximately 380 basis points compared to 11.4% for 2014; versus a prior expectation of 15.0% for 2015;

Adjusted EBITDA margin of approximately 25.4%, an increase of approximately 350 basis points compared to 21.9% for 2014; versus a prior expectation of 25.2% for 2015;

GAAP effective tax expense rate of approximately 43.0%; versus a prior expectation of approximately 45.0% for 2015; and

Non-GAAP effective tax expense rate of approximately 43.0%; versus a prior expectation of approximately 45.0% for 2015.

Supplementary Financial Information

For additional financial detail, please visit the Investor Relations section of the Companys website at

www.nuvasive.com

to access Supplementary Financial Information.

Reconciliation of Full Year EPS Guidance

2015 Guidance

Actuals

Prior

Current

GAAP earnings (loss) per share

(0.36

Impact of change from basic to diluted share count

Impact of treasury method on convertible notes

Adjusted GAAP earnings (loss) per share, adjusted to diluted share count

Amortization of intangible assets

Leasehold related charges

Litigation liability

Intangible asset impairment

CEO transition related costs

One-time and acquisition related items

Non-cash interest expense on convertible notes

Non-GAAP earnings per share

GAAP Weighted shares outstanding - basic

46,715

48,593

GAAP Weighted shares outstanding - diluted

52,607

Non-GAAP Weighted shares outstanding - diluted

49,676

51,431

Effective tax expense rate of ~45% applied to GAAP earnings and ~40% applied to Non-GAAP adjustments

Effective tax expense rate of ~43% applied to GAAP earnings and ~40% applied to Non-GAAP adjustments

Excludes the impact of share dilution of the convertible bond for which the Company has a hedge in place but is...


More